Solid Bio completed a $60 million private placement. The article provides no information on the company’s business model, products, pipeline, or operating metrics. It does not disclose investors or the intended use of proceeds. The report gives no details on prior funding rounds, founding year, or location. The item appeared as a brief news headline alongside coverage of EMA backing five medicines. Solid Biosciences is focused solely on finding meaningful therapies for Duchenne muscular dystrophy (DMD). Its lead candidate, SGT-001, is an adeno-associated viral (AAV) vector-mediated gene therapy with clinical trials anticipated to begin in the second half of 2017. The company is progressing programs across four scientific platforms: Corrective Therapies, Disease Modifying Therapies, Disease Understanding and Assistive Devices. Solid says it will use recent financing to advance SGT-001 into the clinic, secure manufacturing capacity and capabilities, and support long-term clinical and commercial needs. It also plans to continue building its pipeline with next-generation gene therapy assets and disease-modifying therapies. Solid merged with its gene therapy subsidiary Solid GT to better align talent and resources and consolidate their boards.

Total raised

$110M

Funding rounds

2

Latest round

Equity

Latest activity

Jul 2019